Duopharma Biotech to produce second oncology medicine


Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

KUALA LUMPUR: Pharmaceutical firm Duopharma Biotech Bhd, through wholly-owned subsidiary Duopharma HAPI Sdn Bhd, will soon manufacture its second oncology drug at its first-in-Malaysia highly potent active pharmaceutical ingredient (HAPI) Plant in Shah Alam to help address the paucity of affordable alternatives to treat cancer.

Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma Biotech , oncology , cancer , healthcare

   

Next In Business News

UPDATE 1-Amundi to get 26% stake in Victory in exchange for US business
Gold hovers near record high on growing geopolitical concerns
Asian shares slide on US rate cut rethink, Middle East worries
Industry tracker: Samsung returns to top of the smartphone market
OpenAI comes to Asia with new office in Tokyo
FBM KLCI slips further as equities rout continues
Abdul Rahman Ahmad appointed president, chief executive of PNB
China's Q1 GDP growth solid but March data shows feeble demand
KTI Landmark inks underwriting deal with M&A Securities
The pursuit of sustainability by Westports

Others Also Read